Tiziana Life Sciences plc TLSA 深 沪
等待开盘 10-23 09:30:00 美东时间
1.00
-0.010
-0.99%
华盛通- 最 高1.01
- 今 开0.9797
- 成交量 49.40万股
- 最 低 0.94
- 昨 收 1.01
- 总市值 1.27亿
- 52周最高 1.9506
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 0.7615
- 委 比 -98.21%
- 总股本 1.27亿
- 历史最高 12.15
- 量 比 1.31
- 振 幅 6.93%
- 历史最低 0.41
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tiziana Life Sciences收平，成交额59.42万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:57
Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has begun d...
10-16 19:05
Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first three participant...
09-28 19:09
Tiziana Completes Phase 2a MS Trial, Topline Data Due In October
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has comple...
09-21 19:06
Why Is Tiziana Life Sciences Stock Gaining Thursday?
Tiziana Life Sciences Ltd. (NASDAQ:TLSA) said Thursday that it signed a memorandum of understanding to evaluate a combination therapy for patients with relapsing-remitting multiple sclerosis. Following the announcement, the stock jumped by more than 21%. The biotechnology company will collaborate wi...
09-18 01:58
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
Tiziana Life Sciences has signed an MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate on a clinical trial combining intranasal foralumab with anti-CD20 therapy for relapsing-remitting multiple sclerosis (RRMS) patients with poor responses to anti-CD20 therapy alone. The trial aims to address untreated neuroinflammation, leveraging foralumab's ability to reduce neuroinflammation shown in previous studies. The agreement was ...
09-17 11:00
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7
BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.
09-03 18:08
Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled "Phase 2a T...
08-24 19:04
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Tiziana Life Sciences announced the presentation of a Phase 2a trial for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in ALS patients at ALS Nexus 2026. The BANYAN trial, part of the Healey ALS MyMatch program, aims to assess safety, immune modulation biomarkers, and early clinical effects. Foralumab targets the regulatory T cell (Treg) pathway, which is critical in ALS pathogenesis, by expanding and activating Tregs to suppr...
08-24 11:00
